Compounded vs. Brand-Name GLP-1 Medications
Same active ingredient, very different price tag, and very different rules. Here's what's actually changed in 2025-2026, and how to think about which one is right for you.
Reviewed by GlobalGLP1 Editorial Team • Updated May 2026 • Sources: FDA drug shortage list, 503A/503B compounding rules
The Short Version
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are made by Novo Nordisk and Eli Lilly. They are FDA-approved, sold in pharmacies, and cost roughly $1,000 to $1,400 a month without insurance.
Compounded GLP-1 medications are custom-mixed by specialty pharmacies. They contain the same active ingredient (semaglutide or tirzepatide) but they are not FDA-approved as a finished product. They cost roughly $200 to $500 a month at telehealth clinics.
The catch: in 2025, the FDA officially ended the shortages of semaglutide and tirzepatide. That removed the legal cover most pharmacies used to compound them in bulk. Compounded versions still exist, but the rules around them tightened a lot, and access is shrinking.
Side-by-Side Comparison
| Brand-Name Wegovy, Zepbound, Ozempic, Mounjaro |
Compounded semaglutide, tirzepatide |
|
|---|---|---|
| Active ingredient | Semaglutide or tirzepatide | Same (semaglutide or tirzepatide) |
| FDA approved as a finished product? | Yes | No (the active ingredient is, the formulation isn't) |
| Typical cost without insurance | $1,000-$1,400/month | $200-$500/month |
| Insurance coverage | Sometimes (with prior auth, BMI rules) | Almost never |
| Manufacturer savings cards | Available (Novo Nordisk, Eli Lilly) | Not applicable |
| Format | Pre-filled auto-injector pen | Vial and syringe (you draw your dose) |
| Quality oversight | FDA-regulated manufacturing standards | State board of pharmacy + FDA oversight on the pharmacy itself |
| Currently legal in bulk? | Yes | Restricted as of 2025 (see below) |
What Changed in 2025
For most of 2022-2024, Wegovy, Ozempic, Zepbound, and Mounjaro were on the FDA's official drug shortage list. While a drug is on that list, federal law allows specialty compounding pharmacies to mix their own version of the active ingredient and sell it directly to patients or telehealth clinics. That's why compounded GLP-1 medications became so common.
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. Once a drug is off the shortage list, the legal opening for bulk compounding closes. Most large compounding pharmacies stopped selling these medications. A smaller number of state-licensed pharmacies still mix personalized versions one prescription at a time, but the supply is much smaller and the price has crept up.
Translation: if you started on a compounded GLP-1 in 2023 or 2024, the access you had then may not exist now. If you're starting fresh in 2026, you're more likely to land on brand-name with a savings card or a self-pay program (NovoCare, LillyDirect) than on a compounded option.
Are Compounded GLP-1s Safe?
The honest answer: it depends on the pharmacy. The active ingredient itself, semaglutide or tirzepatide, is the same molecule whether it's coming from a Novo Nordisk plant or a compounding pharmacy. What varies is the manufacturing setup around it.
Two things to look for:
- 503B-registered pharmacies have to follow stricter FDA rules and undergo the same kind of inspection as a drug manufacturer. They are the safer end of the compounding spectrum.
- 503A pharmacies compound medications one prescription at a time for a specific patient. They are state-regulated, with lighter federal oversight. Quality varies more here.
The FDA has issued warnings about a handful of compounded semaglutide products that had wrong dosing, contamination, or unapproved additives like B12 or amino acids that were never tested for safety in this combination. A reputable telehealth clinic will tell you which pharmacy compounds their medication and whether it's 503A or 503B. If they can't or won't, that's a red flag.
Why Compounded Costs Less
It's not that the active ingredient is cheaper. The pricing gap comes from three things:
- No R&D recovery built in. Novo Nordisk spent over a decade developing semaglutide and getting it approved for diabetes, then weight loss. Their list price reflects that. Compounding pharmacies didn't fund the development.
- No marketing or sales infrastructure. Brand-name drugs come with sales reps, advertising, patient programs, and rebate systems. Compounded medications come with none of those costs.
- Direct-to-patient model. Compounded GLP-1s usually skip the insurance + retail pharmacy chain. You pay the clinic, the clinic pays the pharmacy, the pharmacy ships you a vial. Each step is leaner.
When Does Each Make Sense?
Brand-name is probably the right call if:
- Your insurance covers Wegovy or Zepbound (check our insurance coverage guide first)
- You qualify for a manufacturer savings card and your copay drops to $25-$150/month
- You want the auto-injector pen rather than drawing your own dose from a vial
- You want the same product that was tested in the clinical trials (the STEP and SURMOUNT studies you've read about used brand-name Wegovy and Zepbound)
- You're enrolled in Medicare or Medicaid (compounded is not covered, and the $2,000 annual Part D cap effective 2025 puts a ceiling on what you'll pay)
Compounded is worth a closer look if:
- You don't have insurance, or your insurance doesn't cover weight loss medication, and the brand-name self-pay programs (NovoCare at ~$499/month for Wegovy, LillyDirect at ~$349-$499/month for Zepbound) are still out of budget
- You're comfortable using a vial and syringe
- You're working with a telehealth clinic that uses a 503B-registered pharmacy and is upfront about who compounds their medication
- You understand that future supply is uncertain (your provider may have to switch you to brand-name later)
A Note on "Personalized" Formulations
You may see telehealth clinics advertising "personalized semaglutide" or "compounded tirzepatide with B12." These are 503A-style formulations where the pharmacy adds something extra (a vitamin, an amino acid, an anti-nausea ingredient) and prescribes it as a one-off custom mix for you specifically. This is the legal workaround some clinics are using post-shortage.
It's not automatically bad, but it's worth asking why the additive is there. If your clinic can explain the medical reason ("we add B12 because nausea-related vitamin loss is common at higher doses"), that's a real answer. If they can't, the additive may exist mostly to justify calling the medication "compounded" so they can keep selling it.
Frequently Asked Questions
The active ingredient (semaglutide) is the same molecule. The finished product is not. Wegovy and Ozempic are FDA-approved manufactured drugs from Novo Nordisk, sold in pre-filled pens with set doses. Compounded semaglutide is mixed by a specialty pharmacy, usually as a vial you draw a dose from. The science of how the drug works in your body is identical, but the manufacturing oversight, format, and price are different.
Not exactly. The FDA ended the official drug shortage status for tirzepatide in late 2024 and semaglutide in early 2025. While these medications were on the shortage list, federal law allowed compounding pharmacies to mix bulk versions and sell them. Now that the shortages are resolved, that legal opening has closed. Some 503A pharmacies still compound personalized one-off prescriptions, but the large-scale supply that powered most telehealth clinics is no longer legal.
It depends heavily on the pharmacy. The active ingredient itself is the same as the brand-name. Risk comes from the manufacturing setup: 503B-registered pharmacies follow stricter FDA-style inspection rules and are the safer option. 503A pharmacies are state-regulated with lighter federal oversight. The FDA has issued warnings about specific compounded products with dosing errors, contamination, or untested additives. Ask your clinic which pharmacy they use and whether it is 503A or 503B before starting.
Three reasons: there is no R&D recovery built into the price (the pharmacy did not develop the drug), there is no marketing or sales infrastructure, and the direct-to-patient model skips the insurance and retail pharmacy chain. Brand-name list prices reflect a decade of clinical trials, FDA approval costs, and a layered distribution system. Compounded skips most of that.
Almost never. Major insurers (Aetna, BCBS, Cigna, UnitedHealthcare), Medicare, and Medicaid all explicitly exclude compounded medications from coverage. They cover the active ingredient when it is dispensed as an FDA-approved finished product (Wegovy, Zepbound, Ozempic, Mounjaro), not when it is mixed by a compounding pharmacy. If insurance coverage matters to you, brand-name is the path.
These are direct-to-patient self-pay programs from the manufacturers themselves, launched in 2024-2025 partly to compete with compounded options. NovoCare offers Wegovy at around $499/month for cash-pay customers. LillyDirect offers Zepbound at around $349 to $499/month depending on dose and supply. They are FDA-approved brand-name medication, with a manufacturer-provided pen, at a price between traditional retail and compounded.
Yes, and many patients are doing exactly that as compounded supply tightens. The active ingredient and dose math is the same, so your provider can move you to a brand-name pen at an equivalent dose. The main differences you will notice are the format (pen vs vial) and the price. If your insurance covers Wegovy or Zepbound, the switch may even cost you less out of pocket than compounded.
Ask three questions: (1) Which pharmacy compounds your medication? (2) Are they 503A or 503B registered? (3) Can you provide a Certificate of Analysis showing the medication has been tested for purity? A reputable clinic will answer all three without hesitation. If they are evasive, that is a meaningful warning sign.
Related Resources
Ready to start treatment?
Search our directory of 2,888 GLP-1 clinics. Filter by medication type, insurance acceptance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. Drug shortage status, compounding pharmacy regulations, and pricing change frequently. Always confirm current availability and safety with a licensed healthcare provider before starting, switching, or stopping any medication.